Quarterly report · Q2
3750.TEDINET S100S7YU
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥863m | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥2.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | −¥354m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | −¥381m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | −¥424m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥862m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥437m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥419m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥539m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥443m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥561m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥443m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | −¥561m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥13.6bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥14.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥14.2bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.4bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥11.4bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.2bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥2.7bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥658m | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥208m | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥673m | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥561m | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥702m | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥367m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥40m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥20m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥283m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥94m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥94m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥294m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥67m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-49.65 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-31.59 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-118.71 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-62.86 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-30.66 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 14.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 17.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥87m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥45m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥45m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥285m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥818m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥818m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥17m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥863m |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥863m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | −¥267m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥74m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥84m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥84m |
| jpcrp040300-q2r_E05443-000Medical Asset Managemetreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥119m |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E05443-000Real Asset Managementreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥188m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | −¥307m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 442
| Item | Context | Value | Unit |
|---|---|---|---|
| Decrease increase in inventories ope cf | Prior1YTDDuration | -22019000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -56618000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 12054000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | -114000 | JPY |
| Decrease increase in investment securities for sale ope cf | Prior1YTDDuration | 337667000 | JPY |
| Decrease increase in investment securities for sale ope cf | CurrentYTDDuration | － | JPY |
| Other net ope cf | Prior1YTDDuration | 3072000 | JPY |
| Other net ope cf | CurrentYTDDuration | 57685000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 78197000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | -287276000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -55744000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -78657000 | JPY |
| Income taxes paid refund ope cf | Prior1YTDDuration | -2603000 | JPY |
| Income taxes paid refund ope cf | CurrentYTDDuration | -1122000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 19849000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | -367057000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -150000000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | － | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -114616000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -3511000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -5600000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | － | JPY |
| Proceeds from sales of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YTDDuration | 198497000 | JPY |
| Proceeds from sales of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYTDDuration | － | JPY |
| Other net inv cf | Prior1YTDDuration | -22035000 | JPY |
| Other net inv cf | CurrentYTDDuration | 18000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -93753000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -3492000 | JPY |
| Increase in short term loans payable fin cf | Prior1YTDDuration | － | JPY |
| Increase in short term loans payable fin cf | CurrentYTDDuration | 100000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 2500000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | － | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -2621914000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -194322000 | JPY |
| Income from acceptance of investments in silent partnerships fin cf | Prior1YTDDuration | 55264000 | JPY |
| Income from acceptance of investments in silent partnerships fin cf | CurrentYTDDuration | － | JPY |
| Other net fin cf | Prior1YTDDuration | 3000 | JPY |
| Other net fin cf | CurrentYTDDuration | -107000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -66646000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -94430000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -140550000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -464980000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 701558000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 673050000 | JPY |
| Decrease in cash and cash equivalents resulting from exclusion of subsidiaries from consolidation cce | Prior1YTDDuration | -150000 | JPY |
| Decrease in cash and cash equivalents resulting from exclusion of subsidiaries from consolidation cce | CurrentYTDDuration | － | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 560857000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 208070000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05443-000MedicalAssetManagemetReportableSegmentsMember | 83682000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05443-000RealAssetManagementReportableSegmentsMember | 1089062000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |